08.08.2022 18:28:00
|
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Global Blood Therapeutics, Inc. (NASDAQ: GBT)'s sale to Pfizer Inc. for $68.50 per share in cash. If you are a Global Blood shareholder, click here to learn more about your rights and options.
Avalara, Inc. (NYSE: AVLR)'s sale to Vista Equity Partners for $93.50 per share. If you are an Avalara shareholder, click here to learn more about your rights and options.
CyberOptics Corporation (NASDAQ: CYBE)'s sale to Nordson Corporation for $54.00 per share. If you are a CyberOptics shareholder, click here to learn more about your rights and options.
Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-notice-halper-sadeh-llp-investigates-gbt-avlr-cybe-301601545.html
SOURCE Halper Sadeh LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Global Blood Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |